Electroanalysis of antitubercular drugs in pharmaceutical dosage forms and biological fluids: A review

Analytica Chimica Acta

Volumn 853, Issue 1, 2015, Pages 59-76

  Thapliyal, Neeta ^a   Karpoormath, Rajshekhar V ^a   Goyal, Rajendra N ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

Antitubercular drugs; Human body fluids; Pharmaceutical formulations; Tuberculosis; Voltammetry

Indexed keywords

BODY FLUIDS; VOLTAMMETRY;

ANTI TUBERCULARS; CHEMICALLY MODIFIED ELECTRODE; ELECTROCHEMICAL TECHNIQUES; HUMAN BODY FLUIDS; PHARMACEUTICAL DOSAGE FORMS; PHARMACEUTICAL FORMULATION; TUBERCULOSIS; VOLTAMMETRIC DETERMINATION;

DRUG DOSAGE;

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CARBON NANOTUBE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ENVIOMYCIN; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; MULTI WALLED NANOTUBE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VIOMYCIN; TABLET;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ALLERGIC REACTION; ALOPECIA; ANALYTIC METHOD; ANOREXIA; ARTHRALGIA; BALANCE DISORDER; BLISTER; BODY FLUID; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; CONVULSION; COORDINATION DISORDER; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG SCREENING; DRUG STRUCTURE; DRUG URINE LEVEL; DRY SKIN; DYSARTHRIA; DYSPNEA; ELECTROANALYSIS; ELECTROCHEMISTRY; ELECTRODE; EMOTIONAL DISORDER; EOSINOPHILIC ENTERITIS; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEART ARREST; HEPATITIS; HOT FLUSH; HUMAN; HYPERIRRITABILITY; HYPERURICEMIA; HYPOTHYROIDISM; ICHTHYOSIS; IMPOTENCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LOSS OF APPETITE; MENORRHAGIA; METALLIC TASTE; MYALGIA; NAUSEA; NEPHROTOXICITY; NERVE INJURY; NEUROTOXICITY; NYSTAGMUS; OBSTRUCTIVE JAUNDICE; OPTIC NEURITIS; ORTHOSTATIC HYPOTENSION; OTOTOXICITY; PAIN; PARALYSIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; POTENTIOMETRY; PROTEINURIA; PRURITUS; PSEUDOMEMBRANOUS COLITIS; PSYCHOSIS; PURPURA; RASH; REVIEW; SALIVATION DISORDER; SEIZURE; SIDEROBLASTIC ANEMIA; SKIN ABRASION; SKIN DISCOLORATION; SKIN SWELLING; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; STRUCTURE ANALYSIS; SWELLING; TASTE DISORDER; TENDON INJURY; TENDON RUPTURE; TINNITUS; TREMOR; UNSPECIFIED SIDE EFFECT; URTICARIA; VALIDATION STUDY; VERTIGO; VESTIBULOCOCHLEAR NERVE DISEASE; VOMITING; BLOOD; CHEMISTRY; ELECTROCHEMICAL ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; TABLET;

ANTITUBERCULAR AGENTS; BODY FLUIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMICAL TECHNIQUES; HUMANS; MASS SPECTROMETRY; TABLETS;

EID: 84922558909     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2014.09.054     Document Type: Review

References (206)

1. Kethireddy S.S. Tuberculosis - a review of clinical features, differential diagnosis and treatments available. Int. J. Pharm. Technol. 2010, 2:206-244.
2. World Health Organisation, Tuberculosis (TB), Global Tuberculosis Report 2013 (2013). Available at: (accessed 08.08.14). http://www.who.int/tb/publications/global_report/en/.
3. World Health Organisation, Tuberculosis, Fact sheet N(104 (2014). Available at: (accessed 08.08.14). http://www.who.int/mediacentre/factsheets/fs104/en/.
4. Caminero J.A., Sotgiu G., Zumla A., Migliori G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010, 10:621-629.
5. Zumla A., Nahid P., Cole S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 2013, 12:388-404.
6. Zumla A., Raviglione M., Hafner R., von Reyn C.F. Tuberculosis. N. Engl. J. Med. 2013, 368:745-755.
7. Rodriguez M.L. Analytical challenges for forensic screening of drugs of abuse. MLO: Med. Lab. Obs. 2012, 44(8):10-11. quiz 16.
8. Siddiqui M.R., AlOthman Z.A., Rahman N. Analytical techniques in pharmaceutical analysis: a review. Arab J. Chem. 2013, in press. 10.1016/arabjc.2013.04.016.
9. Gorog S. Drug safety drug quality, drug analysis. J. Pharm. Biomed. Anal. 2008, 48:247-253.
10. Brittain H.G. The comprehensive profiling of drug substances and pharmaceutical excipients. Preface. Profiles Drug Subst. Excip. Relat. Methodol. 2013, 38. xi.
11. Misiuk W. The role of assay methods in characterizing the quality of bulk pharmaceuticals. J. Pharm. Bioallied Sci. 2010, 2:88-92.
12. Seifart H.I., Kruger P.B., Parkin D.P., van Jaarsveld D.P., Donald D.P. Therapeutic monitoring of antituberculosis drugs by direct in-line extraction on a high-performance liquid chromatography system. J. Chromatogr. 1993, 619:285-290.
13. Revankar S.N., Desai N.D., Vaidya A.B., Bhatt A.D., Anjaneyulu B. Determination of pyrazinamide in human by high performance liquid chromatography. J. Postgrad. Med. 1994, 40:7-9.
14. Fox D., O'Connor R., Mallon P., McMahon G. Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma. J. Pharm. Biomed. Anal. 2011, 56:785-791.
15. Smith P.J., van Dyk J., Fredericks A. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int. J. Tuberc. Lung Dis. 1999, 3:S325-328.
16. Song S.H., Jun S.H., Park K.U., Yoon Y., Lee J.H., Kim J.Q., Song J. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:1331-1338.
17. Granja R.H., Nino A.M., Zucchetti R.A., Nino R.E., Patel R., Salerno A.G. Determination of streptomycin residues in honey by liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta 2009, 637:64-67.
18. Shewiyo D.H., Kaale E., Risha P.G., Dejaegher B., Smeyers-Verbeke J., Vander Heyden Y. Optimization of a reversed-phase-high-performance thin-layer chromatography method for the separation of isoniazid ethambutol, rifampicin and pyrazinamide in fixed-dose combination antituberculosis tablets. J. Chromatogr. A 2012, 1260:232-238.
19. Bate R., Jensen P., Hess K., Mooney L., Milligan J. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int. J. Tuberc. Lung Dis. 2013, 17:308-311.
20. Mohamed A.M.I., Mohamed F.A., Atia N.N., Botros S.M. A novel spectrofluorimetric determination of four anti-TB drugs in their pure and pharmaceutical dosage forms by quenching effect on the fluorescence of NBS-phenothiazine product. Asian J. Biomed. Pharm. Sci. 2013, 3:21-27.
21. Ghoneim M.M., el-Baradie K.Y., Tawfik A. Electrochemical behavior of the antituberculosis drug isoniazid and its square-wave adsorptive stripping voltammetric estimation in bulk form tablets and biological fluids at a mercury electrode. J. Pharm. Biomed. Anal. 2003, 33:673-685.
22. Yang G., Wang C., Zhang R., Wang C., Qu Q., Hu X. Poly(amidosulfonic acid) modified glassy carbon electrode for determination of isoniazid in pharmaceuticals. Bioelectrochemistry 2008, 73:37-42.
23. Mahfouz N.M., Emara K.M. Colorimetric determination of isoniazid and its pharmaceutical formulations. Talanta 1993, 40:1023-1029.
24. Kilic E., Koseoglu F., Akay M.A. The non-aqueous titrimetric assay of selected antibiotics using tetra-N-butylammonium hydroxide as titrant. J. Pharm. Biomed. Anal. 1994, 12:347-352.
25. Marcellos L.F., Faria A.F., de Souza M.V.N., Almeida M.R., Sabin G.P., Poppi R.J., de Oliveira M.A.L. Simultaneous analysis of first-line anti-tuberculosis drugs in tablets by UV spectrophotometry compared to capillary zone electrophoresis. Cent. Eur. J. Chem. 2012, 10:1808-1816.
26. Safavi A., Karimi M.A., Nezhad M.R. Flow injection determination of isoniazid using N-bromosuccinimide- and N-chlorosuccinimide-luminol chemiluminescence systems. J. Pharm. Biomed. Anal. 2003, 30:1499-1506.
27. Ramachandran G., Chandrasekaran V., Hemanth Kumar A.K., Dewan P., Swaminathan S., Thomas A. Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India. Trop. Med. Int. Health 2013, 18:1141-1144.
28. Goyal R.N., Gupta V.K., Oyama M., Bachheti N. Differential pulse voltammetric determination of paracetamol at nanogold modified indium tin oxide electrode. Electrochem. Commun. 2005, 7:803-807.
29. Goyal R.N., Bachheti N., Tyagi A., Pandey A.K. Differential pulse voltammetric determination of methylprednisolone in pharmaceuticals and human biological fluids. Anal. Chim. Acta 2007, 605:34-40.
30. Goyal R.N., Gupta V.K., Bachheti N. Fullerene-C60-modified electrode as a sensitive voltammetric sensor for detection of nandrolone - an anabolic steroid used in doping. Anal. Chim. Acta 2007, 597:82-89.
31. Becker C., Dressman J.B., Amidon G.L., Junginger H.E., Kopp S., Midha K.K., Shah V.P., Stavchansky S., Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. J. Pharm. Sci. 2007, 96:522-531.
32. Khambatta S., Nguyen D.L., Wittich C.M. 38-year-old woman with increasing fatigue and dyspnea. Mayo Clin. Proc. 2010, 85:392-395.
33. Rana F. Rifampicin - an overview. Int. J. Res. Pharm. Chem. 2013, 3:83-87.
34. Rosati C., Cherubini F., Iacomi K., Giannakakis L., Vincenzi G. Acute rifampicin-associated interstitial tubulopathy in a patient with pulmonary tuberculosis: a case report. J. Med. Case Rep. 2013, 7:106/1-106/4.
35. Hui L.S., Cheng H.L., Hui T.L., Mohamad N., Yazid A., Harn G.L. Antituberculosis. Pharm. Sci. 2011, WMC002751/1-WMC002751/13.
36. Becker C., Dressman J.B., Amidon G.L., Junginger H.E., Kopp S., Midha K.K., Shah V.P., Stavchansky S., Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: pyrazinamide. J. Pharm. Sci. 2008, 97:3709-3720.
37. Buyske D.A., Sterling W., Peets E. New antituberculosis agents: laboratory and clinical studies, pharmacological and biochemical studies on ethambutol in laboratory animals. Ann. N.Y. Acad. Sci. 1966, 135:711-725.
38. Graham S.M., Daley H.M., Banerjee A., Salaniponi F.M., Harries A.D. Ethambutol in tuberculosis: time to reconsider?. Arch. Dis. Child. 1998, 79:274-278.
39. Battaglia R., Pianezzola E., Salgarollo G., Zini G., Strolin Benedetti M. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. J. Antimicrob. Chemother. 1990, 26:813-822.
40. Utkin I., Koudriakova T., Thompson T.J., Cottrell C., Iatsimirskaia E., Barry J., Vouros P., Gerber N. Isolation and identification of major urinary metabolites of rifabutin in rats and humans. Drug Metab. Dispos. 1997, 25:963-969.
41. Vassil St Georgiev M.R. Infectious Diseases in Immunocompromised Hosts 1997, CRC Press, Florida.
42. Holdiness Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 1984, 9:511-544.
43. Buggs C.W., Pilling M.A., Bronstein B., Hirshfeld J.W., Worzniak L., Key L.J. The absorption distribution, and excretion of streptomycin in man. J. Clin. Invest. 1946, 25:94-102.
44. Tuazon A.O., Maramba-Lazarte C.C. Antituberculosis drugs. Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice 2010, 492. Lippincott Williams & Wilkins, Philadelphia. fourth ed. S.J. Yaffe, J.V. Aranda (Eds.).
45. Cabana B.E., Taggart J.G. Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans. Antimicrob. Agents Chemother. 1973, 3:478-483.
46. Prasad R., Verma S.K., Sahai S., Kumar S., Jain A. Efficacy and safety of kanamycin, ethionamide PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J. Chest Dis. Allied Sci. 2006, 48:183-186.
47. Bactericidal inhibitors of protein synthesis, the aminoglycosides. The Antimicrobial Drugs 2000, 143. Oxford University Press, New York. second ed. M. Eric Scholar, B. William Pratt (Eds.).
48. Antibacterial agents. The Washington Manual Infectious Diseases Subspecialty Consult 2005, 261. Lippincott Williams & Wilkins. R. Starlin (Ed.).
49. Hock R., Anderson R.J. Prevention of drug-induced nephrotoxicity in the intensive care unit. J. Crit. Care 1995, 10:33-43.
50. Matz G.J. Aminoglycoside cochlear ototoxicity. Otolaryngol. Clin. North Am. 1993, 26:705-712.
51. Dharmadhikari A.S., Kabadi M., Gerety B., Hickey A.J., Fourie P.B., Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob. Agents Chemother. 2013, 57:2613-2619.
52. Schaaf H.S., Seddon J.A., Caminero J.A. Second-line antituberculosis drugs: current knowledge, recent research findings and controversies. Antituberculosis Chemotherapy 2011, 85. Karger Medical and Scientific Publishers. R. Peter Donald, D. Paul Van Helden (Eds.).
53. Reisfeld B., Metzler C.P., Lyons M.A., Mayeno A.N., Brooks E.J., DeGroote M.A. A physiologically based pharmacokinetic model for capreomycin. Antimicrob. Agents Chemother. 2012, 56:926-934.
54. Asif M. Role of aminoglycoside antibiotics in the chemotherapy of Mycobacterium tuberculosis. J. Pharm. Phytother. 2013, 2:1-16.
55. Werner C.A., Adams C., DuBois R. Absorption and excretion of viomycin in humans. Proc. Soc. Exp. Biol. Med. 1951, 76:292-295.
56. Coyne K.M., Pozniak A.L., Lamordeb M., Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009, 23:437-446.
57. Nouaille-Degorce B., Veau C., Dautrey S., Tod M., Laouari D., Carbon C., Farinotti R. Influence of renal failure on ciprofloxacin pharmacokinetics in rat. Antimicrob. Agents Chemother. 1998, 42:289-292.
58. Davis R.L., Koup J.R., Williams-Warren J., Weber A., Smith A.L. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob. Agents Chemother. 1985, 28:74-77.
59. Kim G.K. The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know?. J. Clin. Aesthet. Dermatol. 2010, 3:49-54.
60. Radi A., El-Sherif Z. Determination of levofloxacin in human urine by adsorptive square-wave anodic stripping voltammetry on a glassy carbon electrode. Talanta 2002, 58:319-324.
61. Moorthy N., Raghavendra N., Venkatarathnamma P.N. Levofloxacin-induced acute psychosis. Ind. J. Psychiat. 2008, 50:57-58.
62. Biedenbach D.J., Barrett M.S., Croco M.A.T., Jones R.N. BAY 12-8039, a novel fluoroquinolone: activity against important respiratory tract pathogens. Diagn. Microbiol. Infect. Dis. 1998, 32:45-50.
63. Stass H., Kern A. Moxifloxacin-review of clinical pharmacokinetics: metabolism and excretion. 6th International Symposium on New Quinolones 1998.
64. Bhargava A., Brennan M. Fluoroquinolone-induced hypoglycemia in an overweight nonagenarian with acute kidney injury and not on glucose-lowering therapy. Ann. Long-Term Care: Clin. Care Aging 2014, 22:38-43.
65. Saravolatz L.D., Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 2003, 37:1210-1215.
66. Bitar N., Claes R., der Auwera P.V. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob. Agents Chemother. 1989, 33:1686-1690.
67. van der Linden P.D., van de Lei J., Nab H.W., Knol A., Ch Stricker B.H. Achilles tendinitis associated with fluoroquinolones. Br. J. Clin. Pharmacol. 1999, 48:433-437.
68. Aschenbrenner D.S. Continued reports of peripheral neuropathy with fluoroquinolones. Am. J. Nurs. 2013, 113:23.
69. Naber C.K., Hammer M., Kinzig-Schippers M., Sauber C., Sörgel F., Bygate E.A., Fairless A.J., Machka K., Naber K.G. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob. Agents Chemother. 2001, 45:3524-3530.
70. Grasela D.M. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin. Infect. Dis. 2000, 31:S51-S58.
71. Afzal M., Kazmi I., Khan R., Singh R., Pravez M., Imam F., Anwar F. Pharmacological evaluation of gatifloxacin in chemically induced hepatocarcinogenesis: a new tool for hepatocellular carcinoma treatment. J. Cancer Sci. Ther. 2013, 5:18-22.
72. Arbex M.A., de Castro Lima Varella M., de Siqueira H.R., de Mello F.A.F. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second-line drugs. J. Bras. Pneumol. 2010, 36:641-656.
73. Vora A. Terizidone. J. Assoc. Phys. India 2010, 58:267-268.
74. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. Geneva: World Health Organization, Stop TB Department; 2008. Available at:. (accessed 08.08.14). http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
75. Venkatesan Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin. Pharm. 1989, 16:365-386.
76. Dryden M.S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother. 2011, 66:iv7-iv15.
77. Stalker D.J., Jungbluth G.L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet. 2003, 42:1129-1140.
78. Choi T.A. Miscellaneous antibacterial drugs. Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 2014, 472. J.K. Aronson (Ed.).
79. Nan G.R., Li D. Clinical application of linezolid. Pract. Pharm. Clin. Remedy 2009, 12:403-405.
80. MacGowan A.P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 2003, 51:ii17-ii25.
81. ® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 2004, 53:i3-i20.
82. Behera D. Tuberculosis. Textbook of Pulmonary Medicine 2010, 538. Jaypee Brothers Publishers. second ed.
83. Drusano G.L., Standiford H.C., Bustamante C., Forrest A., Rivera G., Leslie J., Tatem B., Delaportas D., Macgregor R.R., Schimpff S.C. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob. Agents Chemother. 1984, 26:715-721.
84. Calandra G.B., Ricci F.M., Wang C., Brown K.R. Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin. J. Antimicrob. Chemother. 1983, 12:125-131.
85. Norrby S.R., Rogers J.D., Ferber F., Jones K.H., Zacchei A.G., Weidner L.L., Demetriades J.L., Gravallese D.A., Hsieh J.Y. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob. Agents Chemother. 1984, 26:707-714.
86. Tseng K.W.T., Roberts P., Read R.C., Kees F., Wilson R., Cole P.J. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. J. Antimicrob. Chemother. 1994, 33:289-297.
87. Almeida A., Duarte S., Nunes R., Rocha H., Pena A., Meisel L. Human and veterinary antibiotics used in Portugal - a ranking for ecosurveillance. Toxics 2014, 2:188-225.
88. Craft J.C., Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr. Infect. Dis. J. 1993, 12:S142-S147.
89. Jones D.S. The health care experiments at many farms: the navajo, tuberculosis, and the limits of modern medicine, 1952-1962. Bull. Hist. Med. 2002, 76:749-790.
90. McIlleron H., Willemse M., Werely C.J., Hussey G.D., Schaaf H.S., Smith P.J., Donald P.R. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international paediatric dosing guidelines. Clin. Infect. Dis. 2009, 48:1547-1553.
91. Gao Z.N., Han X.X., Yao H.Q., Liang B., Liu W.Y. Electrochemical oxidation of isoniazid catalyzed by (FcM) TMA at the platinum electrode and its practical analytical application. Anal. Bioanal. Chem. 2006, 385:1324-1329.
92. Quintino M.S., Angnes L. Fast BIA-amperometric determination of isoniazid in tablets. J. Pharm. Biomed. Anal. 2006, 42:400-404.
93. Majidi M.R., Jouyban A., Asadpour-Zeynali K. Voltammetric behavior and determination of isoniazid in pharmaceuticals by using overoxidized polypyrrole glassy carbon modified electrode. J. Electroanal. Chem. 2006, 589:32-37.
94. Shahrokhian S., Amiri M. Multi-walled carbon nanotube paste electrode for selective voltammetric detection of isoniazid. Microchim. Acta 2007, 157:149-158.
95. Shahrokhian S., Asadian E. Simultaneous voltammetric determination of ascorbic acid, acetaminophen and isoniazid using thionine immobilized multi-walled carbon nanotube modified carbon paste electrode. Electrochim. Acta 2010, 55:666-672.
96. Asadpour-Zeynali K., Soheili-Azad P. Simultaneous polarographic determination of isoniazid and rifampicin by differential pulse polarography method and support vector regression. Electrochim. Acta 2010, 55:6570-6576.
97. Jena B.K., Raj C.R. Au nanoparticle decorated silicate network for the amperometric sensing of isoniazid. Talanta 2010, 80:1653-1656.
98. Karimi M.A., Hatefi-Mehrjardi A., Mazloum-Ardakani M., Behjatmanesh-Ardakani R., Mashhadizadeh M.H., Sargazi S. Study of electrocatalytic oxidation of isoniazid drug using alizarin red s as a mediator on the glassy carbon electrode. Int. J. Electrochem. Sci. 2010, 5:1634-1648.
99. Bergamini M.F., Santos D.P., Zanoni M.V. Determination of isoniazid in human urine using screen-printed carbon electrode modified with poly-l-histidine. Bioelectrochemistry 2010, 77:133-138.
100. Atta N.F., Galal A., Ahmed R.A. Voltammetric behavior and determination of isoniazid using pedot electrode in presence of surface active agents. Int. J. Electrochem. Sci. 2011, 6:5097-5113.
101. Atta N.F., Galal A., Abu-Attia F.M., Azab S.M. Characterization and electrochemical investigations of micellar/drug interactions. Electrochim. Acta 2011, 56:2510-2517.
102. Yan X., Bo X., Guo L. Electrochemical behaviors and determination of isoniazid at ordered mesoporous carbon modified electrode. Sens. Actuators B Chem. 2011, 155:837-842.
103. Chen W.C., Unnikrishnan B., Chen S.M. Electrochemical oxidation and amperometric determination of isoniazid at functionalized multiwalled carbon nanotube modified electrode. Int. J. Electrochem. Sci. 2012, 7:9138-9149.
104. Szlósarczyk M., Piech R., Bator B.P., Maślanka A., Opoka W., Krzek J. Voltammetric determination of isoniazid using cyclic renewable mercury film silver based electrode. Pharm. Anal. Acta 2012, 3:1000189/1-1000189/5.
105. ®-modified electrode. J. Solid State Electrochem. 2012, 16:2907-2911.
106. de Oliveira P.R., Oliveira M.M., Zarbin A.J.G., Marcolino-Junior L.H., Bergamini M.F. Flow injection amperometric determination of isoniazid using a screen-printed carbon electrode modified with silver hexacyanoferrates nanoparticles. Sens. Actuators B Chem. 2012, 171-172:795-802.
107. Li X., Chen Z., Zhong Y., Yang F., Pan J., Liang Y. Cobalt hexacyanoferrate modified multi-walled carbon nanotubes/graphite composite electrode as electrochemical sensor on microfluidic chip. Anal. Chim. Acta 2012, 710:118-124.
108. Cheemalapati S., Palanisamy S., Chen S.M. Electrochemical determination of isoniazid at electrochemically reduced graphene oxide modified electrode. Int. J. Electrochem. Sci. 2013, 8:3953-3962.
109. Yu H., Jian X., Jin J., Wang F., Wang Y., Qi G.C. Preparation of hybrid cobalt-iron hexacyanoferrate nanoparticles modified multi-walled carbon nanotubes composite electrode and its application. J. Electroanal. Chem. 2013, 700:47-53.
110. Martins P.R., Cerdeira Ferreira L.M., Araki K., Angnes L. Influence of cobalt content on nanostructured alpha-phase-nickel hydroxide modified electrodes for electrocatalytic oxidation of isoniazid. Sens. Actuators B Chem. 2014, 192:601-606.
111. Satyanarayana M., Reddy K.K., Gobi K.V. Multiwall carbon nanotube ensembled biopolymer electrode for selective determination of isoniazid in vitro. Anal. Methods 2014, 6:3772-3778.
112. Devadas S., Chen S.M., Ali M.A., Al-Hemaid F.M.A. Highly sensing graphene oxide/poly-arginine-modified electrode for the simultaneous electrochemical determination of buspirone, isoniazid and pyrazinamide drugs. Ionics 2014, in press. 10.1007/s11581-014-1179-z.
113. Cheemalapati S., Devadas B., Chen S.M., Ali M.A., Al-Hemaid F.M.A. Electrochemical determination of selected antihypertensive and antituberculosis drugs at a tyrosine-modified electrode. Anal. Methods 2014, 6:6774.
114. Cheemalapati S., Chen S.M., Ali M.A., Al-Hemaid F.M.A. Enhanced electrocatalytic oxidation of isoniazid at electrochemically modified rhodium electrode for biological and pharmaceutical analysis. Colloids Surf. B Biointerfaces 2014, 121:444-450.
115. Tyszczuk K., Korolczuk M. New protocol for determination of rifampicine by adsorptive stripping voltammetry. Electroanalysis 2009, 21:101-106.
116. Daneshgar P., Norouzi P., Dousty F., Ganjali M.R., Moosavi-Movahedi A.A. Dysprosium hydroxide nanowires modified electrode for determination of rifampicin drug in human urine and capsules by adsorptive square wave voltammetry. Curr. Pharm. Anal. 2009, 5:246-255.
117. Rastgar S., Shahrokhian S. Nickel hydroxide nanoparticles-reduced graphene oxide nanosheets film: layer-by-layer electrochemical preparation, characterization and rifampicin sensory application. Talanta 2014, 119:156-163.
118. Ajayi R.F., Sidwaba U., Feleni U., Douman S.F., Tovide O., Botha S., Baker P., Fuku X.G., Hamid S., Waryo T.T., Vilakazi S., Tshihkudo R., Iwuoha E.I. Chemically amplified cytochrome P450-2E1 drug metabolism nanobiosensor for rifampicin anti-tuberculosis drug. Electrochim. Acta 2014, 128:149-155.
119. Barco P., Cardoso R.F., Pandolfi J.R. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J. Antimicrob. Chemother. 2006, 58:930-935.
120. Heifets L. Antimycobacterial agents: pyrazinamide. Antimicrobial Therapy and Vaccines 1999, Williams and Wilkins. V.L. Yu, T.C. Merigan, S.L. Barriere (Eds.).
121. Bergamini M.F., Santos D.P., Zanoni M.V.B. Electrochemical behavior and voltammetric determination of pyrazinamide using a poly-histidine modified electrode. J. Electroanal. Chem. 2013, 690:47-52.
122. Cheemalapati S., Devadas B., Chen S.M. Highly sensitive and selective determination of pyrazinamide at poly-l-methionine/reduced graphene oxide modified electrode by differential pulse voltammetry in human blood plasma and urine samples. J. Colloid Interface Sci. 2014, 418:132-139.
123. Lee A.S.G., Othman N.K., Ho Y.M., Wong S.Y. Novel mutations within the embB gene in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2004, 48:4447-4449.
124. Shao C., Wei Y., Li S., Li C. Determination of ethambutol at glassy carbon electrode modified with multiwall carbon nanotubes. Chem. Anal. 2008, 53:511-522.
125. Perantoni C.B., Carbogim L.G.S., Semaan F.S., Matos R.C., Lowinsohn D. Flow injection analysis of ethambutol in antituberculosis drugs using a graphite-paraffin electrode as amperometric detector. Electroanalysis 2011, 23:2582-2585.
126. Perantoni C.B., de Azevedo A.B.R., Vaz F.A.S., de Oliveira M.A.L., Matos R.C., Lowinsohn D. Flow injection analysis of ethambutol in synthetic urine using a graphite-polyurethane composite electrode as an amperometric detector. Cent. Eur. J. Chem. 2013, 11:1668-1673.
127. Comroe J.H. Pay dirt: the story of streptomycin. Part I. From Waksman to Waksman. Am. Rev. Resp. Dis. 1978, 117:773-781.
128. Liu B., Zhang B., Cui Y., Chen H., Gao Z., Tang D. Multifunctional gold-silica nanostructures for ultrasensitive electrochemical immunoassay of streptomycin residues. ACS Appl. Mater. Interfaces 2011, 3:4668-4676.
129. 4@Au - multi-walled carbon nanotubes - chitosan. J. Solid State Electrochem. 2012, 16:857-867.
130. Que X., Liu B., Fu L., Zhuang J., Chen G., Tang D. Molecular imprint for electrochemical detection of streptomycin residues using enzyme signal amplification. Electroanalysis 2013, 25:531-537.
131. Chen Y., Liu L.J., Gao Y., Zhang X.Q., Cao J., Zhang J.K. Development of a voltammetric sensor based on a molecularly imprinted polymer for streptomycin sulfate detection. Chin. J. Anal. Chem. 2014, 42:113-117.
132. Jugheli L., Bzekalava N., de Rijk P., Fissette K., Portaels F., Rigouts L. High level of cross-resistance between kanamycin amikacin, and capreomycin among mycobacterium tuberculosis isolates from georgia and a close relation with mutations in the rrs gene. Antimicrob. Agents Chemother. 2009, 53:5064-5068.
133. Yan J.L. Determinationation of kanamycin by square-wave cathodic adsorptive stripping voltammetry. Russ. J. Electrochem. 2008, 44:1334-1338.
134. Zhao Y., Wei Q., Xu C., Li H., Wu D., Cai Y., Mao K., Cui Z., Du B. Label-free electrochemical immunosensor for sensitive detection of kanamycin. Sens. Actuators B Chem. 2011, 155:618-625.
135. Wei Q., Zhao Y., Du B., Wu D., Li H., Yang M. Ultrasensitive detection of kanamycin in animal derived foods by label-free electrochemical immunosensor. Food Chem. 2012, 134:1601-1606.
136. Zhu Y., Chandra P., Song K.M., Ban C., Shim Y.B. Label-free detection of kanamycin based on the aptamer-functionalized conducting polymer/gold nanocomposite. Biosens. Bioelectron. 2012, 36:29-34.
137. Yu S., Wei Q., Du B., Wu D., Li H., Yan L., Ma H., Zhang Y. Label-free immunosensor for the detection of kanamycin using Ag@Fe(3)O(4) nanoparticles and thionine mixed graphene sheet. Biosens. Bioelectron. 2013, 48:224-229.
138. Sun X., Li F., Shen G., Huang J., Wang X. Aptasensor based on the synergistic contributions of chitosan-gold nanoparticles, graphene-gold nanoparticles and multi-walled carbon nanotubes-cobalt phthalocyanine nanocomposites for kanamycin detection. Analyst 2014, 139:299-308.
139. Labby K.J., Garneau-Tsodikova S. Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections. Future Med. Chem. 2013, 5:1285-1309.
140. Li Y., Li C., Li H., Wang G., Li S. Determination of amikacin by differential pulse cathodic striping voltammetry. Chem. Res. Appl. 2006, 18:1219-1221.
141. Wang X.L., Yu Z.Y., Jiao K. Voltammetric studies on the interaction of amikacin with methyl blue and its analytical application. Chin. Chem. Lett. 2007, 18:94-96.
142. Wang X.L., Wang Z.X., Cai Y.L. CV determination of amikacin with polyaniline nanotubes/chitosan composite film modified glassy carbon electrode. Phys. Test. Chem. Anal. B 2011, 47:407-409.
143. Hsieh W.J., Lin H.C., Hwang S.J., Hou M.C., Lee F.Y., Chang F.Y., Lee D. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am. J. Gastroenterol. 1998, 93:962-966.
144. Torriero A.A.J., Salinas E., Raba J., Silber J.J. Sensitive determination of ciprofloxacin and norfloxacin in biological fluids using an enzymatic rotating biosensor. Biosen. Bioelectron. 2006, 22:109-115.
145. Zhang S., Wei S. Electrochemical determination of ciprofloxacin based on the enhancement effect of sodium dodecyl benzene sulfonate. Bull. Korean Chem. Soc. 2007, 28:543-546.
146. Yi H., Li C. Voltammetric determination of ciprofloxacin based on the enhancement effect of cetyltrimethylammonium bromide (CTAB) at carbon paste electrode. Russ. J. Electrochem. 2007, 43:1377-1381.
147. Uslu B., Bozal B., Kuscu M.E. Anodic voltammetry of ciprofloxacin and its analytical applications. Open Chem. Biomed. Met. J. 2010, 3:108-114.
148. Ming L., Xi X., Sun Y., Liu J. Voltammetric determination of ciprofloxacin hydrochloride on multi-wall carbon nanotube modified electrode. Chin. J. Antibiot. 2009, 34:767-768.
149. Ensafi A.A., Taei M., Khayamian T., Hasanpour F. Simultaneous voltammetric determination of enrofloxacin and ciprofloxacin in urine and plasma using multiwall carbon nanotubes modified glassy carbon electrode by least-squares support vector machines. Anal. Sci. 2010, 26:803-808.
150. Chethana B.K., Naik Y.A. Electrochemical studies of antibiotic drug ciprofloxacin using tyrosine modified carbon paste electrode. Inventi Impact: Med. Chem. 2012, 3:138-145.
151. 4 nanoparticles as a novel electrochemical sensor: application for the voltammetric determination of ciprofloxacin. Anal. Sci. 2012, 28:705-710.
152. Hoang V.D., Nguyen T.Y. Adsorptive cathodic stripping voltammetric determination of ciprofloxacin in bulk powder, pharmaceutical dosage forms and urine. Trop. J. Pharm. Res. 2013, 12:783-790.
153. Zhang F., Gu S., Ding Y., Zhang Z., Li L. A novel sensor based on electropolymerization of β-cyclodextrin and l-arginine on carbon paste electrode for determination of fluoroquinolones. Anal. Chim. Acta 2013, 770:53-61.
154. 2 nanocomposite and its use in construction of a sensitive and selective sensor for determination of ciprofloxacin. Adv. Mater. Res. 2014, 829:563-567.
155. Kawde A.N., Md Abdul Aziz N., Odewunmi, Hassan N., Al Sharaa A. Electroanalytical determination of antibacterial ciprofloxacin in pure form and in drug formulations. Arab. J. Sci. Eng. 2014, 39:131-138.
156. Montes R.H.O., Marra M.C., Rodrigues M.M., Richter E.M., Muñoz R.A.A. Fast determination of ciprofloxacin by batch injection analysis with amperometric detection and capillary electrophoresis with capacitively coupled contactless conductivity detection. Electroanalysis 2014, 26:432-438.
157. Diab N., Abu-Shqair I., Salim R., Al-Subu M. The behavior of ciprofloxacin at a dna modified glassy carbon electrodes. Int. J. Electrochem. Sci. 2014, 9:1771-1783.
158. Al-Ghamdi A.F., Bani-Yaseen A.D. Electrochemical reduction of ciprofloxacin at the mercury electrode and its voltammetric determination in tablet and urine. Russ. J. Electrochem. 2014, 50:355-362.
159. Chi Y., Li J. Determination of levofloxacin hydrochloride with multiwalled carbon nanotubes-polymeric alizarin film modified electrode. Russ. J. Electrochem. 2010, 46:155-160.
160. Wen W., Zhao D.M., Zhang X.H., Xiong H.Y., Wang S.F., Chen W., Zhao Y.D. One-step fabrication of poly(o-aminophenol)/multi-walled carbon nanotubes composite film modified electrode and its application for levofloxacin determination in pharmaceuticals. Sens. Actuators B Chem. 2012, 174:202-209.
161. Moraes F.C., Silva T.A., Cesarino I., Lanza M.R.V., Machado S.A.S. Antibiotic detection in urine using electrochemical sensors based on vertically aligned carbon nanotubes. Electroanalysis 2013, 25:2092-2099.
162. 2 rods for levofloxacin detection. J. Braz. Chem. Soc. 2014, 25:502-508.
163. Wang F., Zhu L., Zhang J. Electrochemical sensor for levofloxacin based on molecularly imprinted polypyrrole-graphene-gold nanoparticles modified electrode. Sens. Actuators B Chem. 2014, 192:642-647.
164. Trindade M.A.G., Cunha P.A.C., de Araújo T.A., da Silva G.M., Ferreira V.S. Interaction study of moxifloxacin with Cu(II) ion using square-wave voltammetry and its application in the determination in tablets. Ecletica Quim. 2006, 31:31-38.
165. Inam R., Mercan H., Yilmaz E., Uslu B. Differential pulse polarographic determination of moxifloxacin hydrochloride in pharmaceuticals and biological fluids. Anal. Lett. 2007, 40:529-546.
166. Radi A.E., Wahdan T., Anwar Z., Mostafa H. Electrochemical determination of gatifloxacin, moxifloxacin and sparfloxacin fluoroquinolonic antibiotics on glassy carbon electrode in pharmaceutical formulations. Drug Test. Anal. 2010, 2:397-400.
167. Long N., Zhu M.F., Yan Z.H., Zou Y. Anodic adsorptive voltammetric determination of moxifloxacin hydrochloride. Phys. Test. Chem. Anal. B 2012, 48:37-39.
168. Khalid S., Gauhar S., Rehman R., Fatima S. Post market surveillance of different brands of ofloxacin 200mg tablets available in local market of Karachi (Pakistan). Int. J. Pharm. Pharm. Sci. 2012, 4:668-672.
169. Yang C.H., Zhang S.H., Liu Y.X., Huang W.S. Electrochemical behavior of ofloxacin at carbon nanotubes film electrode and its voltammetric determination. Front. Chem. China 2008, 3:353-358.
170. Huang K.J., Liu X., Xie W.Z., Yuan H.X. Voltammetric behavior of ofloxacin and its determination using a multi-walled carbon nanotubes-nafion film coated electrode. Microchim. Acta 2008, 162:227-233.
171. Al-Ghamdi A.F. A study of adsorptive stripping voltammetric behavior of ofloxacine antibiotic in the presence of Fe(III) and its determination in tablets and biological fluids. J. Saudi Chem. Soc. 2009, 13:235-241.
172. Gandhi S., Mehta V., Rajput S. Simultaneous voltammetric determination of nitazoxanide and ofloxacin in pharmaceutical formulation. Ind. J. Pharm. Sci. 2011, 73:583-586.
173. Ribeiro F.W.P., Soares T.R.V., do S., Oliveira N., Melo L.C., Soares J.E., Becker H., de Souza D., de Lima-Neto P., Correia A.N. Analytical determination of nimesulide and ofloxacin in pharmaceutical preparations using square-wave voltammetry. J. Anal. Chem. 2014, 69:62-71.
174. Zhou G., Jiang Y., Sun Y., Zheng Q. Electrocatalysis actions of poly(crystal violet) film modified electrodes on ofloxacin. Chin. J. Pharm. Anal. 2007, 27:201-203.
175. Yang C., Xu Y., Hu C., Hu S. Voltammetric detection of ofloxacin in human urine at a congo red functionalized water-soluble carbon nanotube film electrode. Electroanalysis 2008, 20:144-149.
176. 4/MWCNTs nanocomposite modified GC electrode for electrochemical determination of ofloxacin. J. Nanosci. Nanotechnol. 2014, 14:5059-5069.
177. Han H., Li J.Z., Pang X.Z. Electrochemical sensor using glassy carbon electrode modified with HPMαFP/Ppy/GCE composite film for determination of ofloxacin. Int. J. Electrochem. Sci. 2013, 8:9060-9070.
178. El-Desoky H.S. Stability indicating square-wave stripping voltammetric method for determination of gatifloxacin in pharmaceutical formulation and human blood. J. Braz. Chem. Soc. 2009, 20:1790-1799.
179. Radi A.E., Wahdan T., Anwar Z., Mostafa H. Electrochemical determination of gatifloxacin, moxifloxacin and sparfloxacin fluoroquinolonic antibiotics on glassy carbon electrode in pharmaceutical formulations. Drug Test Anal. 2010, 2:397-400.
180. Ramadan A.A., Mandil H. Determination of gatifloxacin in pure form and pharmaceutical formulations by differential pulse polarographic analysis. Anal. Biochem. 2010, 404:1-7.
181. Zhang F., Gu S., Ding Y., Li L., Liu X. Simultaneous determination of ofloxacin and gatifloxacin on cysteic acid modified electrode in the presence of sodium dodecyl benzene sulfonate. Bioelectrochemistry 2013, 89:42-49.
182. Ghoneim M.M., El-Attar M.A. Adsorptive stripping voltammetric determination of antibiotic drug clarithromycin in bulk form, pharmaceutical formulation and human urine. Chem. Anal. 2008, 53:689-702.
183. Stevens D.L., Dotter B., Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev. Anti. Infect. Ther. 2004, 2:51-59.
184. Merli D., Pretali L., Fasani E., Albini A., Profumo A. Analytical determination and electrochemical characterization of the oxazolidinone antibiotic linezolid. Electroanalysis 2011, 23:2364-2372.
185. Santos D.P., Bergamini M.F., Zanoni M.V.B. Voltammetric sensor for amoxicillin determination in human urine using polyglutamic acid/glutaraldehyde film. Sens. Actuators B Chem. 2008, 133:398-403.
186. Rezaei B., Damiri S. Electrochemistry and adsorptive stripping voltammetric determination of amoxicillin on a multiwalled carbon nanotubes modified glassy carbon electrode. Electroanalysis 2009, 21:1577-1586.
187. Chiu M.H., Chang J.L., Zen J.M. An analyte derivatization approach for improved electrochemical detection amoxicillin. Electroanalysis 2009, 21:1562-1567.
188. Fouladgar M., Hadjmohammadi M.R., Khalilzadeh M.A., Biparva P., Teymoori N., Beitollah H. Voltammetric determination of amoxicillin at the electrochemical sensor ferrocenedicarboxylic acid multi wall carbon nanotubes paste electrode. Int. J. Electrochem. Sci. 2011, 6:1355-1366.
189. Ojani R., Raoof J.B., Zamani S. A novel voltammetric sensor for amoxicillin based on nickel-curcumin complex modified carbon paste electrode. Bioelectrochemistry 2012, 85:44-49.
190. 4, a new selective electrochemical sensor for amoxicillin determination. J. Nanopart. Res. 2012, 14:1244/1-1244/11.
191. Brahman P.K., Dar R.A., Pitre K.S. Conducting polymer film based electrochemical sensor for the determination of amoxicillin in micellar media. Sens. Actuators B Chem. 2013, 176:307-314.
192. Chowdhury T.R., Shaikh A.A., Akter H., Neaz M.M., Bakshi P.K., Ahammad A.J.S. Highly sensitive detection of amoxicillin based on gold nanoparticle-modified ITO electrode. ECS Solid State Lett. 2014, 3:P14-P16.
193. Fernández-Torres R., Navarro M.V., López M.A.B., Mochón M.C., Sánchez J.C.J. Urea as new stabilizing agent for imipenem determination electrochemical study and determination of imipenem and its primary metabolite in human urine. Talanta 2008, 77:241-248.
194. Leandro K.C., de Carvalho J.M., Giovanelli L.F., Moreira J.C. Development and validation of an electroanalytical methodology for determination of isoniazid and rifampicin content in pharmaceutical formulations. Braz. J. Pharm. Sci. 2009, 45:331-337.
195. Ni Y., Wang Y., Kokot S. Simultaneous determination of three fluoroquinolones by linear sweep stripping voltammetry with the aid of chemometrics. Talanta 2006, 69:216-225.
196. Abdel Ghani N.T., El-Ries M.A., El-Shall M.A. Validated polarographic methods for the determination of certain antibacterial drugs. Anal. Sci. 2007, 23:1053-1058.
197. Madhusudana Reddy T., Balaji K., Jayarama Reddy S. Voltammetric behavior of some fluorinated quinolone antibacterial agents and their differential pulse voltammetric determination in drug formulations and urine samples using a β-cyclodextrin-modified carbon-paste electrode. J. Anal. Chem. 2007, 62:168-175.
198. Boo H., Song Y.J., Park S., Chung T.D. Determination of fluoroquinolone antibacterial agents by square wave adsorptive stripping voltammetry. J. Korean Electrochem. Soc. 2010, 13:63-69.
199. Ding Y., Bai L., Suo X., Meng X. Post separation adjustment of pH to enable the analysis of aminoglycoside antibiotics by microchip electrophoresis with amperometric detection. Electrophoresis 2012, 33:3245-3253.
200. Chen T.S., Huang K.L., Chen J.L. An electrochemical approach to simultaneous determination of acetaminophen and ofloxacin. Bull. Environ. Contam. Toxicol. 2012, 89:1284-1288.
201. Sabitha P., Ratna J.V., Reddy K.R. A new RP-HPLC method for the determination of isoniazid in plasma. Drug Invention Today 2010, 2:331-334.
202. Khuhawar M.Y., Rind F.M.A. Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood. J. Chromatogr. B 2002, 766:357-363.
203. Song S.H., Jun S.H., Park K.U., Yoon Y., Lee J.H., Kim J.Q., Song J. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:1331-1338.
204. Zhou Z., Wu X., Wei Q., Liu Y., Liu P., Ma A., Zou F. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma. Anal. Bioanal. Chem. 2013, 405:6323-6335.
205. Siddhartha T.S., Prasanthi B., Santosh T., Ratna J.V. Development and validation of high performance liquid chromatographic method for the determination of pyrazinamide in human plasma. J. Pharm. Res. 2013, 7:33-38.
206. Gao W., Fang P., Li H., Zhang F., Zhao X. Determination of ethambutol hydrochloride in tablets by high performance liquid chromatography with charge aerosol detection (HPLC-CAD). Cent. South Pharm. (Zhongnan Yaoxue) 2009, 7:338-340.